MedTrace Logo

Trial for People With Established Type 2 Diabetes During Ramadan

NCT02292290 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2020-01-30

No results posted yet for this study

Summary

Dual therapy with metformin and Liraglutide is more effective at helping people with established Type 2 Diabetes Mellitus (T2DM) observing Ramadan achieve a triple composite endpoint of weight reduction and/or maintenance and improved HaemaglobinA1c (HbA1c) and no severe hypoglycaemic events.

Conditions

Interventions

DRUG

Liraglutide

4 week lead-in 0.6mg Liraglutide OD up to 1.2mg OD after 2 weeks if poor response

DRUG

Liraglutide

4 week lead-in 0.6mg Liraglutide OD up to 1.2mg after two weeks if poor response.

DRUG

Sulfonylurea or Pioglitazone

Addition to Metformin

DRUG

Maintain dual therapy (Sulf/Pio) as comparator to Liraglutide

As per clinical guidelines for prescription

Sponsors & Collaborators

  • University Hospitals, Leicester

    collaborator OTHER

  • University Hospital Birmingham

    collaborator OTHER

  • University of Leicester

    lead OTHER

Principal Investigators

  • Melanie J D · University of Leicester

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02292290 on ClinicalTrials.gov